BioCentury
ARTICLE | Politics, Policy & Law

Second wind for importation

Why Marathon’s pricing of Emflaza is breathing new life into drug importation

February 25, 2017 2:39 AM UTC

Outrage over Marathon Pharmaceuticals LLC’s pricing of Emflaza deflazacort has breathed new life into proposals for FDA to make it easier to import lower drug prices.

Marathon quickly put its commercialization plans for the Duchenne muscular dystrophy (DMD) drug on hold in response to intense criticism of its planned $89,000 annual wholesale acquisition cost (WAC) for a corticosteroid that families routinely import from Canada or the U.K. for $1,200 to $1,500 a year. Nevertheless, Emflaza continues to serve as a rallying cry for proponents of importation and other drug price control strategies. ...

BCIQ Company Profiles

Marathon Pharmaceuticals LLC